These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Identification of Immune Subtypes for Predicting the Prognosis of Patients in Head and Neck Squamous Cell Carcinoma. Sun J; Fang G; Zuo Z; Yu X; Xue L; Li C; Li S Technol Cancer Res Treat; 2021; 20():15330338211045823. PubMed ID: 34657509 [TBL] [Abstract][Full Text] [Related]
23. A comprehensive analysis of immune infiltration in the tumor microenvironment of osteosarcoma. Yang H; Zhao L; Zhang Y; Li FF Cancer Med; 2021 Aug; 10(16):5696-5711. PubMed ID: 34258887 [TBL] [Abstract][Full Text] [Related]
24. Single-Cell Transcriptome Analysis Reveals Different Immune Signatures in HPV- and HPV + Driven Human Head and Neck Squamous Cell Carcinoma. Li S; Wang Y; Sun R; Franceschi D; Pan H; Wei C; Ogbuehi AC; Lethaus B; Savkovic V; Gaus S; Zimmerer R; Ziebolz D; Schmalz G; Jiang X J Immunol Res; 2022; 2022():2079389. PubMed ID: 36157879 [TBL] [Abstract][Full Text] [Related]
25. Identification of hub genes and potential therapeutic mechanisms related to HPV positive head and neck squamous carcinoma based on full transcriptomic detection and ceRNA network construction. Wang K; Zhang T; Li X; Zhang X; Li R; Pan B; Deng J Gene; 2024 Jun; 910():148321. PubMed ID: 38428621 [TBL] [Abstract][Full Text] [Related]
26. Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma. Lim SM; Kang SS; Kim DK; Lee SH; Synn CB; Baek S; Yang SM; Han YJ; Kim MH; Han H; Na K; Kim YT; Yun MR; Kim JH; Byeon Y; Kim YS; Lee JB; Hong MH; Curtin JC; Patel B; Bergiers I; Pyo KH; Cho BC Cancer Res Commun; 2024 Jul; 4(7):1748-1764. PubMed ID: 38916448 [TBL] [Abstract][Full Text] [Related]
27. The Immune Infiltration in HNSCC and Its Clinical Value: A Comprehensive Study Based on the TCGA and GEO Databases. Sun X; Zhang L; Liu S Comput Math Methods Med; 2021; 2021():1163250. PubMed ID: 34790249 [TBL] [Abstract][Full Text] [Related]
28. HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer. Miyauchi S; Sanders PD; Guram K; Kim SS; Paolini F; Venuti A; Cohen EEW; Gutkind JS; Califano JA; Sharabi AB Cancer Res; 2020 Feb; 80(4):732-746. PubMed ID: 31848196 [TBL] [Abstract][Full Text] [Related]
29. Enhancement of Tumor Antigen-specific T-cell Responses by Immune Checkpoint Blockade in Human Papillomavirus-related Head and Neck Squamous Cell Carcinoma. Chikamatsu K; Ida S; Masuda K; Horikawa M; Hoshino N; Takahashi H; Tada H; Oyama T; Takeda S; Tomidokoro Y; Motegi M Anticancer Res; 2024 Jul; 44(7):2921-2931. PubMed ID: 38925841 [TBL] [Abstract][Full Text] [Related]
30. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy. Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476 [TBL] [Abstract][Full Text] [Related]
32. High expression of CLEC10A in head and neck squamous cell carcinoma indicates favorable prognosis and high-level immune infiltration status. Zou M; Wu H; Zhou M; Xiao F; Abudushalamu G; Yao Y; Zhao F; Gao W; Yan X; Fan X; Wu G Cell Immunol; 2022 Feb; 372():104472. PubMed ID: 35093731 [TBL] [Abstract][Full Text] [Related]
33. DOCK8 Serves as a Prognostic Biomarker and Is Related to Immune Infiltration in Patients With HPV Positive Head and Neck Squamous Cell Carcinoma. Zhang Z; Bao Y; Zhou L; Ye Y; Fu W; Sun C Cancer Control; 2021; 28():10732748211011951. PubMed ID: 33910393 [TBL] [Abstract][Full Text] [Related]
34. Bioinformatic analysis identifies HPV-related tumor microenvironment remodeling prognostic biomarkers in head and neck squamous cell carcinoma. Zhou Q; Yuan O; Cui H; Hu T; Xiao GG; Wei J; Zhang H; Wu C Front Cell Infect Microbiol; 2022; 12():1007950. PubMed ID: 36425786 [TBL] [Abstract][Full Text] [Related]
35. Wei Z; Shen Y; Zhou C; Cao Y; Deng H; Shen Z Bioengineered; 2022 May; 13(5):13784-13800. PubMed ID: 35712757 [TBL] [Abstract][Full Text] [Related]
36. Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma. Xu X; Li R; Zhang L; Zhu G; Ren D; Wu L; Gong X Diagn Pathol; 2021 Nov; 16(1):110. PubMed ID: 34823553 [TBL] [Abstract][Full Text] [Related]
37. Upregulated glycolysis correlates with tumor progression and immune evasion in head and neck squamous cell carcinoma. Takahashi H; Kawabata-Iwakawa R; Ida S; Mito I; Tada H; Chikamatsu K Sci Rep; 2021 Sep; 11(1):17789. PubMed ID: 34493792 [TBL] [Abstract][Full Text] [Related]
38. A meta-validated immune infiltration-related gene model predicts prognosis and immunotherapy sensitivity in HNSCC. Ding Y; Chu L; Cao Q; Lei H; Li X; Zhuang Q BMC Cancer; 2023 Jan; 23(1):45. PubMed ID: 36639648 [TBL] [Abstract][Full Text] [Related]